Searched for
BIOSIMILARS MARKET EVALUATION
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Sun Pharma to stay disciplined on M&A, says Dilip ShanghviSun Pharma plans a careful acquisition strategy. The company prioritizes organic growth to remain an attractive investment. Chairman Dilip ...
- Sun Pharmaceutical to adopt a 'disciplined' approach to M&A: Dilip ShanghviAsked about the strategic priorities in the US, he added: "Not only the US, but we have interest in selling innovative medicines globally.....
- ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar ShawBiocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves...
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...
- Biocon weighs sale of $1.5 billion generic API businessThe Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for ...
- Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilarsDr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...
- No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma"I think our preliminary assessment indicates that vaccines will require a dedicated manufacturing facility and it cannot be produced in a ...
- Pfizer to halt biosimilar output in China, sell assets to WuXi BiologicsThe pharmaceutical industry increasingly relies for its profits on costly biologic drugs, made from living organisms that are tougher and m...
- Changes proposed in norms to speed up approvals for biosimilarsBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- Make in India: Can India be a hub for the $200 billion worth biosimilars opportunityThe Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
- Biocon Q3 net up 9 pc at Rs 93 croreNet sales of the company rose to Rs 634.22 crore for the third quarter, as against Rs 516.59 crore during the same period of 2011-12 fiscal.
- 'We have a conservative generic policy'Robert Sheroff, president, Global Pharmaceutical Supply Group (GPSG) spoke to Nina Mehta about the company’s plans in the country.
- Panacea, Intas plan biosimilar launchJoining Indian pharma majors who are targeting the $65-billion global biotech drug market.
- Now, make way for the biotech copycatsIndian drug makers have already become a formidable force in bringing out generic forms of chemically-synthesised medicines, especially in ...
Load More
